NKY(300109)2024-04-25 16:08Financial Performance - The company's revenue for Q1 2024 was approximately ¥394.69 million, representing an increase of 8.73% compared to ¥363.00 million in the same period last year[4]. - Net profit attributable to shareholders was approximately ¥121.39 million, a slight increase of 1.17% from ¥119.98 million year-over-year[4]. - The net profit after deducting non-recurring gains and losses was approximately ¥125.86 million, up 6.21% from ¥118.51 million in the previous year[4]. - The total operating revenue for the first quarter of 2024 was CNY 394,687,984.97, an increase of 8.5% compared to CNY 363,003,583.47 in the same period last year[22]. - The net profit for Q1 2024 was CNY 120,924,966.70, a slight increase from CNY 119,313,647.55 in Q1 2023, representing a growth of 1.35%[24]. - The total operating profit for Q1 2024 was CNY 143,346,308.66, down from CNY 154,728,205.01 in Q1 2023, a decrease of 7.5%[24]. - The company reported a total comprehensive income of CNY 120,752,326.83 for Q1 2024, compared to CNY 119,468,991.30 in the same period last year, marking an increase of 1.07%[25]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 23.39% to approximately ¥129.32 million, compared to ¥104.81 million in the same period last year[4]. - The cash and cash equivalents at the end of the first quarter of 2024 were CNY 255,081,248.87, down from CNY 290,774,860.62 at the beginning of the period, indicating a decrease of approximately 12.3%[19]. - The cash and cash equivalents at the end of Q1 2024 were CNY 236,999,722.70, a decrease from CNY 419,287,701.29 at the end of Q1 2023[27]. - The company incurred a net cash outflow from investing activities of CNY 138,217,291.74, compared to CNY 180,410,623.98 in the previous year, showing an improvement of 23.4%[27]. Assets and Liabilities - Total assets at the end of Q1 2024 were approximately ¥4.11 billion, reflecting a 2.24% increase from ¥4.02 billion at the end of the previous year[4]. - The total assets as of the end of the first quarter of 2024 were CNY 4,109,820,467.94, an increase from CNY 4,019,691,116.69 at the beginning of the period[21]. - The company’s total liabilities decreased to CNY 461,582,575.44 from CNY 499,660,569.81, a reduction of about 7.6%[20]. - The company’s non-current assets totaled CNY 2,945,457,235.82, up from CNY 2,832,688,738.62, reflecting a growth of approximately 4.0%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,082[11]. - Wang Donghu holds 8.70% of shares, amounting to 28,063,481 shares, with 15,880,000 shares pledged[11]. - Wuhu Great Wall Guolong Investment Management Co., Ltd. holds 3.91% of shares, totaling 12,623,491 shares, with shares frozen[11]. - Wang Jianqiang holds 3.26% of shares, amounting to 10,531,834 shares, with some shares frozen[11]. - The total number of shares held by the top ten shareholders includes significant stakes from natural persons and investment companies[12]. - The company has 29,870,990 shares under lock-up, with various executives holding significant amounts[15]. - The company has a total of 29,833,040 shares under lock-up, with various executives and employees involved in stock incentive plans[15]. Investment Activities - The company plans to invest RMB 20 million in Huadao (Shanghai) Biomedical Co., Ltd., acquiring 11.5969% of its equity[16]. - The company will invest RMB 30 million in Beijing Zhongqi Huiyun Technology Co., Ltd., obtaining 10% of its equity[16]. - The company’s board approved a proposal for a private placement of A-shares, which was later rejected in the shareholders' meeting[16]. Expenses and Financial Metrics - The company reported a significant increase in financial expenses, which rose by 122.15% to approximately -¥2.85 million due to increased interest on purchased time deposits[9]. - The company experienced a 191.02% increase in credit impairment losses, amounting to approximately -¥3.20 million, attributed to increased provisions for receivables[9]. - The company reported a decrease in government subsidies recognized, which fell by 56.04% to approximately ¥1.39 million compared to ¥3.16 million in the previous year[9]. - The company reported research and development expenses of CNY 13,658,788.28 for the first quarter of 2024, which is an increase of 23.1% compared to CNY 11,097,533.95 in the previous year[22]. - The company's basic earnings per share decreased by 2.56% to ¥0.38, while diluted earnings per share increased by 2.70% to ¥0.38[4]. - The weighted average return on equity was 3.36%, down from 3.75% in the previous year[4]. - The total operating costs for the first quarter of 2024 were CNY 243,186,782.84, up 17.0% from CNY 207,845,510.81 in the previous year[22].